Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
President Trump signed Executive Order 14297 to implement Most-Favored-Nation (MFN) pricing for prescription drugs, requiring Medicare to pay no more than the lowest price paid in other developed nations. The order aims to reduce drug costs for American patients and Medicare spending by allowing the government to negotiate lower pharmaceutical prices based on international benchmarks.
On March 3, 2025, President Trump signed Executive Order 14228, further amending duties addressing the synthetic opioid supply chain originating from China. The order modifies existing tariff or enforcement mechanisms related to Chinese opioid precursors and related materials. Confirmed direct impacts on Americans include altered costs for pharmaceutical inputs and potential effects on opioid treatment medication availability and pricing.
On February 10, 2025, President Trump signed Proclamation 2025-02833 adjusting imports of steel into the United States. The proclamation modifies tariff rates on steel products entering the country. The confirmed direct impact includes changed pricing and availability of steel for American manufacturers, construction projects, and consumers purchasing steel-containing goods.
Executive Order 14195 was signed on February 1, 2025, directing the imposition of duties on synthetic opioids and precursor chemicals sourced from China. The order establishes tariffs and trade restrictions on these substances to disrupt supply chains. The confirmed direct impact includes increased costs for pharmaceutical manufacturers and potential effects on opioid medication availability and pricing for Americans.
On July 22, 2019, the Trump administration issued Presidential Determination 2019-15995 under Section 303 of the Defense Production Act of 1950, invoking authority to prioritize and allocate materials deemed necessary for national defense. The determination expanded federal authority to direct production and allocation of specified strategic materials. The direct impact on Americans included potential prioritization of certain manufacturing resources for defense purposes and possible effects on commercial availability and pricing of affected materials.